Hospital Acquired Infection Control Market Size to Hit USD 42.65 Billion by 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Hospital Acquired Infection Control Market

5.1. COVID-19 Landscape: Hospital Acquired Infection Control Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Hospital Acquired Infection Control Market, By Component

8.1. Hospital Acquired Infection Control Market, by Component

8.1.1. Consumables

8.1.1.1. Market Revenue and Forecast

8.1.2. Equipment

8.1.2.1. Market Revenue and Forecast

8.1.3. Services

8.1.3.1. Market Revenue and Forecast

Chapter 9. Global Hospital Acquired Infection Control Market, By End-Use

9.1. Hospital Acquired Infection Control Market, by End-Use

9.1.1. Hospitals & ICUs

9.1.1.1. Market Revenue and Forecast

9.1.2. Ambulatory Surgical Centers

9.1.2.1. Market Revenue and Forecast

9.1.3. Clinics & Others

9.1.3.1. Market Revenue and Forecast

Chapter 10. Global Hospital Acquired Infection Control Market, By Infection Type

10.1. Hospital Acquired Infection Control Market, by Infection Type

10.1.1. Surgical Site Infections

10.1.1.1. Market Revenue and Forecast

10.1.2. Urinary Tract Infections

10.1.2.1. Market Revenue and Forecast

10.1.3. Bloodstream Infections

10.1.3.1. Market Revenue and Forecast

10.1.4. Others

10.1.4.1. Market Revenue and Forecast

Chapter 11. Global Hospital Acquired Infection Control Market, By Technology

11.1. Hospital Acquired Infection Control Market, by Technology

11.1.1. Sterilization Technology

11.1.1.1. Market Revenue and Forecast

11.1.2. Disinfection Technology

11.1.2.1. Market Revenue and Forecast

Chapter 12. Global Hospital Acquired Infection Control Market, By Distribution Channel

12.1. Hospital Acquired Infection Control Market, by Distribution Channel

12.1.1. Direct Sales

12.1.1.1. Market Revenue and Forecast

12.1.2. Distributors

12.1.2.1. Market Revenue and Forecast

Chapter 13. Global Hospital Acquired Infection Control Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Component

13.1.2. Market Revenue and Forecast, by End-Use

13.1.3. Market Revenue and Forecast, by Infection Type

13.1.4. Market Revenue and Forecast, by Technology

13.1.5. Market Revenue and Forecast, by Distribution Channel

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Component

13.1.6.2. Market Revenue and Forecast, by End-Use

13.1.6.3. Market Revenue and Forecast, by Infection Type

13.1.6.4. Market Revenue and Forecast, by Technology

13.1.6.5. Market Revenue and Forecast, by Distribution Channel

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Component

13.1.7.2. Market Revenue and Forecast, by End-Use

13.1.7.3. Market Revenue and Forecast, by Infection Type

13.1.7.4. Market Revenue and Forecast, by Technology

13.1.7.5. Market Revenue and Forecast, by Distribution Channel

13.2. Europe

13.2.1. Market Revenue and Forecast, by Component

13.2.2. Market Revenue and Forecast, by End-Use

13.2.3. Market Revenue and Forecast, by Infection Type

13.2.4. Market Revenue and Forecast, by Technology

13.2.5. Market Revenue and Forecast, by Distribution Channel

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Component

13.2.6.2. Market Revenue and Forecast, by End-Use

13.2.6.3. Market Revenue and Forecast, by Infection Type

13.2.7. Market Revenue and Forecast, by Technology

13.2.8. Market Revenue and Forecast, by Distribution Channel

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Component

13.2.9.2. Market Revenue and Forecast, by End-Use

13.2.9.3. Market Revenue and Forecast, by Infection Type

13.2.10. Market Revenue and Forecast, by Technology

13.2.11. Market Revenue and Forecast, by Distribution Channel

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Component

13.2.12.2. Market Revenue and Forecast, by End-Use

13.2.12.3. Market Revenue and Forecast, by Infection Type

13.2.12.4. Market Revenue and Forecast, by Technology

13.2.13. Market Revenue and Forecast, by Distribution Channel

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Component

13.2.14.2. Market Revenue and Forecast, by End-Use

13.2.14.3. Market Revenue and Forecast, by Infection Type

13.2.14.4. Market Revenue and Forecast, by Technology

13.2.15. Market Revenue and Forecast, by Distribution Channel

13.3. APAC

13.3.1. Market Revenue and Forecast, by Component

13.3.2. Market Revenue and Forecast, by End-Use

13.3.3. Market Revenue and Forecast, by Infection Type

13.3.4. Market Revenue and Forecast, by Technology

13.3.5. Market Revenue and Forecast, by Distribution Channel

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Component

13.3.6.2. Market Revenue and Forecast, by End-Use

13.3.6.3. Market Revenue and Forecast, by Infection Type

13.3.6.4. Market Revenue and Forecast, by Technology

13.3.7. Market Revenue and Forecast, by Distribution Channel

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Component

13.3.8.2. Market Revenue and Forecast, by End-Use

13.3.8.3. Market Revenue and Forecast, by Infection Type

13.3.8.4. Market Revenue and Forecast, by Technology

13.3.9. Market Revenue and Forecast, by Distribution Channel

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Component

13.3.10.2. Market Revenue and Forecast, by End-Use

13.3.10.3. Market Revenue and Forecast, by Infection Type

13.3.10.4. Market Revenue and Forecast, by Technology

13.3.10.5. Market Revenue and Forecast, by Distribution Channel

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Component

13.3.11.2. Market Revenue and Forecast, by End-Use

13.3.11.3. Market Revenue and Forecast, by Infection Type

13.3.11.4. Market Revenue and Forecast, by Technology

13.3.11.5. Market Revenue and Forecast, by Distribution Channel

13.4. MEA

13.4.1. Market Revenue and Forecast, by Component

13.4.2. Market Revenue and Forecast, by End-Use

13.4.3. Market Revenue and Forecast, by Infection Type

13.4.4. Market Revenue and Forecast, by Technology

13.4.5. Market Revenue and Forecast, by Distribution Channel

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Component

13.4.6.2. Market Revenue and Forecast, by End-Use

13.4.6.3. Market Revenue and Forecast, by Infection Type

13.4.6.4. Market Revenue and Forecast, by Technology

13.4.7. Market Revenue and Forecast, by Distribution Channel

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Component

13.4.8.2. Market Revenue and Forecast, by End-Use

13.4.8.3. Market Revenue and Forecast, by Infection Type

13.4.8.4. Market Revenue and Forecast, by Technology

13.4.9. Market Revenue and Forecast, by Distribution Channel

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Component

13.4.10.2. Market Revenue and Forecast, by End-Use

13.4.10.3. Market Revenue and Forecast, by Infection Type

13.4.10.4. Market Revenue and Forecast, by Technology

13.4.10.5. Market Revenue and Forecast, by Distribution Channel

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Component

13.4.11.2. Market Revenue and Forecast, by End-Use

13.4.11.3. Market Revenue and Forecast, by Infection Type

13.4.11.4. Market Revenue and Forecast, by Technology

13.4.11.5. Market Revenue and Forecast, by Distribution Channel

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Component

13.5.2. Market Revenue and Forecast, by End-Use

13.5.3. Market Revenue and Forecast, by Infection Type

13.5.4. Market Revenue and Forecast, by Technology

13.5.5. Market Revenue and Forecast, by Distribution Channel

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Component

13.5.6.2. Market Revenue and Forecast, by End-Use

13.5.6.3. Market Revenue and Forecast, by Infection Type

13.5.6.4. Market Revenue and Forecast, by Technology

13.5.7. Market Revenue and Forecast, by Distribution Channel

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Component

13.5.8.2. Market Revenue and Forecast, by End-Use

13.5.8.3. Market Revenue and Forecast, by Infection Type

13.5.8.4. Market Revenue and Forecast, by Technology

13.5.8.5. Market Revenue and Forecast, by Distribution Channel

Chapter 14. Company Profiles

14.1. 3M

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. STERIS

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Ecolab

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Getinge

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Cantel Medical

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Advanced Sterilization Products

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Sterigenics

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Belimed

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. MMM Group

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Midmark Corporation

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at [email protected]

Frequently Asked Questions

Answer : The hospital acquired infection control market size was evaluated at USD 22.30 billion in 2025 to USD 42.65 billion by 2035.

Answer : The hospital acquired infection control market is expected to grow at a compound annual growth rate (CAGR) of around 6.70% from 2026 to 2035.

Answer : The major players in the hospital acquired infection control market include 3M, STERIS, Ecolab, Getinge, Cantel Medical, Advanced Sterilization Products, Sterigenics, Belimed, MMM Group, Midmark Corporation, Cardinal Health, Halyard Health, Metrex Research, Diversey, and Becton, Dickinson and Company.

Answer : The driving factors of the hospital acquired infection control market are the rising incidences of hospital-acquired infections and demand for advanced infection prevention solutions.

Answer : North America region will lead the global hospital acquired infection control market during the forecast period 2026 to 2035.